Key result
CGS 35601 reduced mean arterial blood pressure by 10%, 22%, and 40% at doses of 0.1, 1, and 5 mg/kg/d respectively in spontaneously hypertensive rats.
Why the study?
Does CGS 35601 (triple vasopeptidase inhibitor) reduce blood pressure in spontaneously hypertensive rats compared to single or dual vasopeptidase inhibitors?
Does CGS 35601 (triple vasopeptidase inhibitor) reduce blood pressure in spontaneously hypertensive rats compared to single or dual vasopeptidase inhibitors?
The triple vasopeptidase inhibitor CGS 35601 dose-dependently reduced blood pressure in spontaneously hypertensive rats, demonstrating superior blood pressure-lowering effects compared to single or dual inhibitors.
Authors
No takes yet. Share an insight, caveat, or question.
Triple VPI effects in SHR models warrant exploration; leaves open translation to human hypertension therapy.
Daull et al. (2005) studied Hypertension. CGS 35601 vs. Saline vehicle and selective ACE, ACE+NEP, and ACE+NEP+ECE inhibitors was evaluated on mean arterial blood pressure. CGS 35601 reduced mean arterial blood pressure by 10%, 22%, and 40% at doses of 0.1, 1, and 5 mg/kg/d respectively in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: